Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial
Diabetes Obesity and Metabolism2023Vol. 25(5), pp. 1229–1240
Citations Over TimeTop 23% of 2023 papers
Linong Ji, Xiaozhen Jiang, Qingshun Hao, Zhifeng Cheng, Kun Wang, Shuguang Pang, Mei‐Ying Liu, Yushan Guo, Xiaowen Chen, Xiuhai Su, Tao Ning, Jie Liu, Fang Bian, Yulan Li, Zhinong Zhang, Weihong Song, Jingfang Sun
Abstract
Janagliflozin 25 mg and 50 mg monotherapy once-daily effectively improved glycaemic control, reduced body weight and blood pressure, improved HDL cholesterol and insulin sensitivity, and was generally well tolerated.
Related Papers
- → Novel aspects of postprandial lipemia in relation to atherosclerosis(2008)93 cited
- → Determinant of postprandial triglyceride levels in healthy young adults(2019)9 cited
- → Update on postprandial hyperglycemia: The pathophysiology, prevalence, consequences and implications of treating diabetes(2018)11 cited
- Correlation research of the elderly postprandial hypotension and vascular endothelial function(2012)
- [Postprandial hyperglycemia].(2003)